查看購物車
  • Simplified Chinese
  • English
  • Japanese
連接酶市場 - 全球和區域分析：按產品、產地、應用、最終用戶、國家 - 分析和預測（2025-2035 年）
市場調查報告書
商品編碼
1711585

連接酶市場 - 全球和區域分析：按產品、產地、應用、最終用戶、國家 - 分析和預測（2025-2035 年）

Ligase Market - A Global and Regional Analysis: Focus on Product, Source, Application, End User, and Country - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 110 Pages | 商品交期: 1-5個工作天內

價格

預測期內，即 2025-2035 年，全球連接酶市場規模預計將以 5.61% 的複合年成長率擴張。

預計全球連接酶市場的成長將受到以下因素的推動：全球感染疾病和遺傳病的流行率不斷上升、人們對基於酶的診斷測試的認知不斷提高以及開展研發的資金充足。

全球連接酶市場正在快速發展，用於疾病檢測的各種連接酶產品的研發活動顯著增加，凸顯了連接酶在醫療保健中的重要性。連接酶在分子診斷方法中起著關鍵作用，確保了標靶治療藥物的安全有效應用。全球連接酶市場上的大多數公司都提供連接試劑套件和含酶的產品。

增加基於酶的分子診斷的研發投資是連接酶市場的主要機會之一。多家診斷和製藥公司正在合作進行藥物開發，利用連接酶作為多種疾病的治療工具，實現高效的診斷、治療方法選擇、劑量選擇和治療監測。

在連接酶的開發中已經採用了幾種技術來檢測和量化特定的 DNA 或 RNA 序列。此連接酶市場領域細分為連接酶鍊式反應 (LCR)、連接酶檢測反應 (LDR)、次世代定序(NGS)、重複擴增檢測 (RED)、滾環擴增 (RCA)、鄰位連接分析 (PLA)、分子克隆、連接介導的 PCR、突變檢測和其他應用，如藥物發現目標。

  • 連接酶鍊式反應 (LCR)：LCR 是一種擴增過程，與聚合酵素鏈鎖反應(PCR) 相反，它涉及使用耐熱連接酶將兩個探針或不同的粒子連接在一起，然後按照標準 PCR 循環進行擴增。
  • 連接酶檢測反應（LDR）：LDR 是一種依靠連接酶鍊式反應（LCR）將一對互補探針連接到目標 DNA 單鏈上的方法。此技術利用基於高保真度的耐熱 DNA 連接酶，可以區分錯配探針的連接。
  • 次世代定序(NGS)：次世代定序使用 DNA 連接酶來識別 DNA 序列中特定位置處核苷酸的存在或不存在。這種定序作用依賴 DNA 連接酶明確識別和連接鹼基的能力。
  • 連接介導的 PCR：連接介導的 PCR 過程使得無需從大分子（例如擴增的酵母人工染色體 (YAC)）進行亞克隆即可產生原型定序模板。

按產品領域分類，T4 DNA 連接酶預計將佔據主導地位。這是由於 T4 DNA 連接酶的使用日益增多，它是套件和酶供應商向最終用戶提供的最常用的酶。

全球連接酶市場以大腸桿菌衍生產品為主。大腸桿菌連接酶是一種常用的連接酶，用於在將分子引入細胞之前連接其重組末端。從大腸桿菌中可以大量獲得T4 RNA連接酶、T4 DNA連接酶、大腸桿菌DNA連接酶、鹽T4 DNA連接酶等產品。

分子克隆過程在應用領域佔據主導地位，而NGS則在全球連接酶市場中用於新興診斷。隨著各種克隆技術（屬於分子克隆）的發展，這種程序的使用也越來越廣泛，DNA片段重組的難度和速度也越來越快。

在全球連接酶市場中，研究機構和實驗室佔據最終用戶領域，特別是因為有許多研究機構進行專注於確定連接酶的診斷應用的研究。

全球連接酶市場的最新趨勢

  • 2022年1月，ArcticZymes Technologies推出了ArcticZymes R2DTM Ligase、IsoPol BST+High Concentration Glycerol FREE、M-SAN HQ ELISA Kit、M-SAN HQ等新產品。
  • 2022 年 4 月，Codexis, Inc. 和 Molecular Assemblies, Inc. 合作，為酵素工程和 DNA 酶促合成提供差異化、經濟高效的解決方案。
  • 2022 年 5 月，QIAGEN 收購了 BLIRT eu 96% 的股份，BLIRT eu 是一家位於波蘭格但斯克的生命科學產業重組酶製造商。此次收購旨在為酵素和試劑業務提供進一步的成長潛力。
  • 2021年7月，默克公司向位於達姆施塔特的全球總部投資2.825億美元。默克公司正在為其醫療保健業務部門建立一個新的轉化科學中心和一個新的學習中心。

產品/創新策略：本報告將連接酵素套件和酵素都視為基於產品的公司。這些公司正積極推行關鍵業務策略，將研發成功轉化為商業性臨床環境。

成長/行銷策略：大規模平行定定序及其應用的爆炸性成長正在影響醫療保健的所有領域，特別是基於酵素的分子診斷。連接酶市場的主要組成部分包括各種基於連接酶的產品和連接試劑套件，通常由測試公司和測試服務機構自行購買。該報告提供了整個工作流程的詳細說明，以及考慮用於檢查的應用程式的定價分析。

競爭策略：分析並描述全球連結酶市場的主要企業概況。此外，它還對全球連字市場中的參與企業進行了詳細的競爭基準化分析，以呈現清晰的市場格局，幫助讀者了解參與企業之間的競爭情況。此外，夥伴關係、協議和聯盟等全面的競爭策略可幫助讀者了解市場中尚未開發的收益來源。

本報告概述了全球連接酶市場，包括按產品、產地、應用、最終用戶和國家分類的趨勢，以及參與市場的公司概況。

目錄

執行摘要

第1章 市場概述

  • 概述
  • 主要趨勢
  • 專利分析
  • 監管分析
  • 定價分析

第2章 市場動態

  • 概述
    • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

第3章全球連結酶市場：競爭格局

  • 概述
  • 企業策略
  • 商務策略
  • 市場佔有率分析

第4章 全球連結酶市場（按產品類型分類）（百萬美元），2023 年至 2035 年

  • 概述
  • 快速連接酶
  • T4 DNA連接酶
  • 大腸桿菌DNA連接酶
  • Tth DNA連接酶
  • T4 RNA連接酶
  • Pfu DNA連接酶
  • 其他

第5章 全球連結酶市場（按來源分類）（百萬美元），2023 年至 2035 年

  • 概述
  • 古菌
  • 大腸桿菌
  • 嗜熱菌
  • 激烈火球菌
  • 其他

第6章 全球連結酶市場（按應用分類）（百萬美元），2023 年至 2035 年

  • 概述
  • 連接酶鍊式反應（LCR）
  • 連接酶檢測反應（LDR）
  • 次世代定序（NGS）
  • 重複增強檢測（RED）
  • 滾圓放大器（RCA）
  • 鄰位連接試驗（PLA）
  • 分子克隆
  • 連接介導PCR
  • 突變檢測
  • 其他

第7章 全球連結酶市場，按最終用戶分類（百萬美元），2023 年至 2035 年

  • 概述
  • 實驗室和研究機構
  • 製藥和生物製藥公司
  • 診斷實驗室
  • 其他

第8章 全球連結酶市場（按地區分類）（百萬美元），2023 年至 2035 年

  • 概述
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 荷蘭
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 中東
    • 非洲

第9章 公司簡介

  • Agilent Technologies, Inc.
  • ArcticZymes Technologies ASA
  • BD
  • Bio-Rad Laboratories, Inc.
  • Codexis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Inspiralis Limited, Inc.
  • Merck KGaA
  • New England Biolabs（UK）Ltd.
  • Promega Corporation
  • QIAGEN NV
  • SBS Genetech
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • Emerging Companies
Product Code: BHL1220SB

Global Ligase Market Industry Overview

The global ligase market is expected to grow at a CAGR of 5.61% during the forecast period from 2025 to 2035. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.

Market Lifecycle Stage

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes.

Increasing investments in the R&D for enzyme-based molecular diagnostics is one of the major opportunities in the ligase market. Several diagnostics and pharmaceutical companies are working collaboratively on drug development and using ligase as a therapeutic means for applications in several disease indications in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring.

Impact

Several techniques are employed in the development of ligase utilization to detect and quantify specific DNA or RNA sequences. This ligase market space has been segmented into applications that includes ligase chain reaction (LCR), ligase detection reaction (LDR), next-generation sequencing (NGS), repeat expansion detection (RED), rolling circle amplification (RCA), proximity ligation assay (PLA), molecular cloning, ligation mediated PCR, mutation detection, and other application such as drug target. Some of these technologies are described briefly as follows:

  • Ligase chain reaction (LCR): LCR is an amplification process that contrasts with polymerase chain reaction (PCR), which includes a thermostable ligase to join two probes or different particles together, which can then be amplified by standard PCR cycling.
  • Ligase detection reaction (LDR): LDR is a ligase chain reaction (LCR) dependent methodology which that involves a single pair of complementary probes to one strand of targeted DNA. This technique utilizes a high fidelity based thermostable DNA ligase that can distinguish against the ligation of mismatched probes.
  • Next-generation sequencing (NGS): In next-generation sequencing, DNA ligase is used to identify the presence of the nucleotide at a specific position in a DNA sequence. The role of this sequencing depends upon the ability of DNA ligase to identify and consolidate bases in an unmistakable way.
  • Ligation mediated PCR: The process of ligation mediated PCR allows to generate prototypical sequencing templates without subcloning from huge molecules, for example-., amplified yeast artificial chromosomes (YACs).

Market Segmentation:

Segmentation 1: by Product

  • Quick Ligase
  • T4 DNA ligase
  • E. coli DNA Ligase
  • Tth DNA Ligase
  • T4 RNA Ligase
  • Pfu DNA Ligase
  • Others

The global ligase market in the products segment is expected to be dominated by T4 DNA ligase. This is due to an increased usage of T4 DNA ligase, and it is the most commonly used ligase type among suppliers offering kits and enzymes to their end users.

Segmentation 2: by Source

  • Archaebacterium
  • Escherichia coli
  • Thermus thermophilus
  • Pyrococcus furiosus
  • Others

The global ligase market is dominated by the Escherichia coli source as it is a commonly used ligase to join recombinant ends of molecules before they are introduced into the cell. Products like T4 RNA ligase, T4 DNA ligase, E. coli DNA ligase, and salt T4 DNA ligase are obtained from Escherichia coli in abundance.

Segmentation 3: by Application

  • Ligase Chain Reaction (LCR)
  • Ligase Detection Reaction (LDR)
  • Next-Generation Sequencing (NGS)
  • Repeat Expansion Detection (RED)
  • Rolling Circle Amplification (RCA)
  • Proximity Ligation Assay (PLA)
  • Molecular Cloning
  • Ligation Mediated PCR
  • Mutation Detection
  • Others

The molecular cloning process dominates the application segment and NGS is the emerging diagnostic application in the global ligase market. The increase in the utilization of this procedure is due to various cloning techniques that have been created that fall under molecular cloning to improve the ease and speed at which DNA fragments can be recombined.

Segmentation 4: by End User

  • Research Laboratories and Institutions
  • Pharmaceutical and Biopharmaceutical Companies
  • Diagnostic Laboratories
  • Others

The research laboratories and institutions dominate the end-user segment in the global ligase market as research laboratories, particularly are most involved in carrying out the research studies that are focused on the identification of understanding the diagnostic application of ligase enzyme.

Recent Developments in Global Ligase Market

  • In January 2022, ArcticZymes Technologies launched new products such as ArcticZymes R2DTM Ligase, IsoPol BST+ High Concentration Glycerol FREE and M-SAN HQ ELISA Kit and M-SAN HQ
  • In April 2022, Codexis, Inc. and Molecular Assemblies, Inc., partnered to engineer enzymes and deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA.
  • In May 2022, QIAGEN acquired majority stake of 96% in BLIRT e.u.., a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. The acquisition was carried out to bring companies capabilities to create additional growth prospects to their enzymes and reagents business.
  • In July 2021, Merck invested $282.5 million at its global headquarters in Darmstadt. Company is involved in building a new translational science center for its healthcare business sector as well as a new learning center.

Demand - Drivers and Limitations

Following are the demand drivers for the global ligase market:

  • Growing need for Ligases in Disease Treatment
  • Rising Incidence of Diseases such as Cancer and Genetic Disorders
  • Rising Focus of Researchers on Non-Toxic Biocatalyst

The market is expected to face some limitations too due to the following challenges:

  • High Reception Costs Involving Small and Medium Enterprises
  • Variation in the Ability of Ligase to Repair

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The report considers ligase kits and enzymes both from the product-based companies. These companies are actively involved in undertaking significant business strategies to translate success in research and development into the commercial clinical setting.

Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of healthcare have been affected, particularly enzyme-based molecular diagnostics. The key components in the ligase market consists of diverse range of ligase-based products and ligation kits, generally purchased by the testing companies and the testing services themselves. The entire workflow is well explained in the report along with pricing analysis considering the applications that are used in testing.

Competitive Strategy: Key players in the global ligase market analysed and profiled in the study, consisting of both products-based companies as well as few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the global ligase market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The leading top segment players include ligase enzyme manufacturers that offers major products such as T4 DNA ligase, and E.coli DNA ligase, quick ligase, Pfu DNA ligase, T4 RNA ligase in the market.

Some of the prominent names established in this market are:

  • Agilent Technologies, Inc.
  • ArcticZymes Technologies ASA
  • BD
  • Bio-Rad Laboratories, Inc.
  • Codexis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • New England Biolabs (UK) Ltd.
  • Promega Corporation
  • QIAGEN N.V.
  • SBS Genetech
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

Research Methodology

1. Market Overview

  • 1.1 Overview
  • 1.2 Key Trends
  • 1.3 Patent Analysis
  • 1.4 Regulatory Analysis
  • 1.5 Pricing Analysis

2. Market Dynamics

  • 2.1 Overview
    • 2.1.1 Impact Analysis
  • 2.2 Market Drivers
  • 2.3 Market Restraints
  • 2.4 Market Opportunities

3. Global Ligase Market: Competitive Landscape

  • 3.1 Overview
  • 3.2 Corporate Strategies
    • 3.2.1 Mergers and Acquisitions
    • 3.2.2 Synergistic Activities
    • 3.2.3 Business Expansions and Funding
  • 3.3 Business Strategies
    • 3.3.1 Product Launches and Approvals
    • 3.3.2 Publications
    • 3.3.3 Licenses and Agreements
    • 3.3.4 Other Activities
  • 3.4 Market Share Analysis

4. Global Ligase Market (by Product Type), ($Million), 2023-2035

  • 4.1 Overview
  • 4.2 Quick Ligase
  • 4.3 T4 DNA Ligase
  • 4.4 E. coli DNA Ligase
  • 4.5 Tth DNA Ligase
  • 4.6 T4 RNA Ligase
  • 4.7 Pfu DNA Ligase
  • 4.8 Others

5. Global Ligase Market (by Source Type), ($Million), 2023-2035

  • 5.1 Overview
  • 5.2 Archaebacterium
  • 5.3 Escherichia coli
  • 5.4 Thermus thermophilus
  • 5.5 Pyrococcus furiosus
  • 5.6 Others

6. Global Ligase Market (by Application), ($Million), 2023-2035

  • 6.1 Overview
  • 6.2 Ligase Chain Reaction (LCR)
  • 6.3 Ligase Detection Reaction (LDR)
  • 6.4 Next-Generation Sequencing (NGS)
  • 6.5 Repeat Expansion Detection (RED)
  • 6.6 Rolling Circle Amplification (RCA)
  • 6.7 Proximity Ligation Assay (PLA)
  • 6.8 Molecular Cloning
  • 6.9 Ligation Mediated PCR
  • 6.10 Mutation Detection
  • 6.11 Others

7. Global Ligase Market (by End User), ($Million), 2023-2035

  • 7.1 Overview
  • 7.2 Research Laboratories and Institutions
  • 7.3 Pharmaceutical and Biopharmaceutical Companies
  • 7.4 Diagnostic Laboratories
  • 7.5 Other End Users

8. Global Ligase Market (by Region), ($Million), 2023-2035

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 France
    • 8.3.3 U.K
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Netherlands
    • 8.3.7 Rest-of-Europe
  • 8.4 Asia-Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest-of-Asia-Pacific (RoAPAC)
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest-of-Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Middle East
    • 8.6.2 Africa

9. Company Profiles

  • 9.1 Agilent Technologies, Inc.
    • 9.1.1 Company Overview
    • 9.1.2 Product Portfolio
    • 9.1.3 Target Customers/End Users
    • 9.1.4 Analyst View
  • 9.2 ArcticZymes Technologies ASA
    • 9.2.1 Company Overview
    • 9.2.2 Product Portfolio
    • 9.2.3 Target Customers/End Users
    • 9.2.4 Analyst View
  • 9.3 BD
    • 9.3.1 Company Overview
    • 9.3.2 Product Portfolio
    • 9.3.3 Target Customers/End Users
    • 9.3.4 Analyst View
  • 9.4 Bio-Rad Laboratories, Inc.
    • 9.4.1 Company Overview
    • 9.4.2 Product Portfolio
    • 9.4.3 Target Customers/End Users
    • 9.4.4 Analyst View
  • 9.5 Codexis, Inc.
    • 9.5.1 Company Overview
    • 9.5.2 Product Portfolio
    • 9.5.3 Target Customers/End Users
    • 9.5.4 Analyst View
  • 9.6 F. Hoffmann-La Roche Ltd.
    • 9.6.1 Company Overview
    • 9.6.2 Product Portfolio
    • 9.6.3 Target Customers/End Users
    • 9.6.4 Analyst View
  • 9.7 Inspiralis Limited, Inc.
    • 9.7.1 Company Overview
    • 9.7.2 Product Portfolio
    • 9.7.3 Target Customers/End Users
    • 9.7.4 Analyst View
  • 9.8 Merck KGaA
    • 9.8.1 Company Overview
    • 9.8.2 Product Portfolio
    • 9.8.3 Target Customers/End Users
    • 9.8.4 Analyst View
  • 9.9 New England Biolabs (UK) Ltd.
    • 9.9.1 Company Overview
    • 9.9.2 Product Portfolio
    • 9.9.3 Target Customers/End Users
    • 9.9.4 Analyst View
  • 9.10 Promega Corporation
    • 9.10.1 Company Overview
    • 9.10.2 Product Portfolio
    • 9.10.3 Target Customers/End Users
    • 9.10.4 Analyst View
  • 9.11 QIAGEN N.V.
    • 9.11.1 Company Overview
    • 9.11.2 Product Portfolio
    • 9.11.3 Target Customers/End Users
    • 9.11.4 Analyst View
  • 9.12 SBS Genetech
    • 9.12.1 Company Overview
    • 9.12.2 Product Portfolio
    • 9.12.3 Target Customers/End Users
    • 9.12.4 Analyst View
  • 9.13 Takara Bio Inc.
    • 9.13.1 Company Overview
    • 9.13.2 Product Portfolio
    • 9.13.3 Target Customers/End Users
    • 9.13.4 Analyst View
  • 9.14 Thermo Fisher Scientific, Inc.
    • 9.14.1 Company Overview
    • 9.14.2 Product Portfolio
    • 9.14.3 Target Customers/End Users
    • 9.14.4 Analyst View
  • 9.15 Emerging Companies
    • 9.15.1 Tinzyme Ltd.
    • 9.15.2 Hotspot Therapeutics
    • 9.15.3 Nurix Therapeutics
    • 9.15.4 Vividion Therapeutics

List of Figures

  • Figure: Global Ligase Market, Dynamics Impact Analysis
  • Figure: Global Ligase Market Coverage
  • Figure: Global Ligase Market, Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Ligase Market, Patent Analysis, January 2022-March 2025
  • Figure: Global Ligase Market, Competitive Landscape, January 2022-March 2025

List of Tables

  • Table: Global Ligase Market Dynamics, Impact Analysis
  • Table: Global Ligase Market (by Product Type), $Million, 2023-2035
  • Table: Global Ligase Market (by Source Type), $Million, 2023-2035
  • Table: Global Ligase Market (by Application), $Million, 2023-2035
  • Table: Global Ligase Market (by End User), $Million, 2023-2035
  • Table: Global Ligase Market (Region), $Million, 2023-2035